Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448370 · ClinicalTrials.gov registry record
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- 136
- Enrollment target
NCT00448370: Completed study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT00448370 is a clinical trial that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 136 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00448370 has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- 136 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out whether Placenta Growth Factor (PlGF) and related tests can predict the development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) during a period where patients are well and during admission to the hospital for an acute sickle event to see if these measures can predict the development of ACS. Understanding events precipitating ACS may lead to preventative and interventional therapies which will improve patient outcomes and quality of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2007-03 |
What the finished NCT00448370 record still lists
NCT00448370 is an observational study that tracks outcomes without assigning an intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00448370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00448370 about?
NCT00448370 is a clinical study titled "Role of Placenta Growth Factor in Sickle Acute Chest Syndrome". The purpose of this research study is to find out whether Placenta Growth Factor (PlGF) and related tests can predict the development of acute chest syndrome (ACS) in patients with sickle cell disease (SCD) during a period where patients are well and during admission to the hospital for an acute sic...
What is the current status of trial NCT00448370?
This trial is currently completed. The enrollment target is 136 participants. The study started on 2007-03.
Who is sponsoring clinical trial NCT00448370?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia